What is Ocrevus and how is it used for MS treatment?
Ocrevus, also known as ocrelizumab, is a medication used to treat multiple sclerosis (MS). It is a monoclonal antibody that targets and depletes certain immune cells that contribute to the disease progression. MS is an autoimmune disorder where the immune system mistakenly attacks the protective covering of the nerves, leading to inflammation and damage.
How does Ocrevus work on the immune system? [1]
Ocrevus works by targeting and binding to CD20, a protein found on the surface of certain immune cells called B cells and plasma cells. By binding to CD20, Ocrevus induces apoptosis (cell death) of these cells, thus reducing their numbers and subsequent production of inflammatory compounds. This reduction in immune cell activity helps to decrease the inflammation and damage caused by the disease.
Clinical trials and efficacy of Ocrevus
Clinical trials have shown that Ocrevus is effective in reducing the number of relapses, slowing the progression of physical disability, and reducing or halting the accumulation of lesions in the brain and spinal cord. [2] A phase III trial published in the New England Journal of Medicine showed that patients treated with Ocrevus had significantly fewer relapses and a decrease in disease activity compared to those receiving placebo.
Potential benefits and considerations
While Ocrevus has shown promise in treating MS, there are potential risks and considerations to be aware of. Common side effects include infusion reactions, upper respiratory tract infections, and increased risk of infections such as pneumonia. Serious side effects, though rare, include lymphocyte count decreases and potential increased risk of malignancies. [3] Patients and healthcare providers should discuss the potential benefits and risks of Ocrevus treatment.
References:
[1] DrugPatentWatch.com (2023): Ocrevus (Ocrelizumab) - Patent Summary - www.drugpatentwatch.com
[2] Hauser et al. (2017). Ocrelizumab versus Placebo in Relapsing Multiple Sclerosis. New England Journal of Medicine, 376(8), 673-684 - www.nejm.org/doi/10.1056/NEJMoa1703543
[3] US FDA (2020): Ocrevus (Ocrelizumab) - Prescribing Information - www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s011bl.pdf